metricas

Radiología (English Edition)

Suggestions
Radiología (English Edition) Quantifying steatosis in the liver and pancreas with MRI in patient with chronic...
Journal Information
Vol. 62. Issue 3.
Pages 165-248 (May - June 2020)
Cite
Cite
Share
Download PDF
More article options
Visits
2621
Vol. 62. Issue 3.
Pages 165-248 (May - June 2020)
Original articles

Quantifying steatosis in the liver and pancreas with MRI in patient with chronic liver disease

Cuantificación por resonancia magnética de esteatosis hepáticas y pancreáticas en hepatopatías crónicas
Visits
2621
J. Vieiraa,
Corresponding author
joaopfsvieira@gmail.com

Corresponding author.
, J. Amorimb,c,d, L. Martí-Bonmatíe, Á. Alberich-Bayarrie,f, M. Françaa,b,g
a Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidad de Oporto, Oport, Portugal
b Departamento de Diagnóstico por la Imagen, Centro Hospitalar do Porto, Oport, Portugal
c Escola de Medicina, Universidade do Minho, Braga, Portugal
d ICVS/3B’s, Instituto de Investigación de Ciencias de la Vida y la Salud, Universidade do Minho, Braga, Portugal
e Departamento de Radiología y Grupo de Investigación Biomédica en Imagen GIBI230. Hospital Universitario y Politécnico La Fe e Instituto de Investigación Sanitaria La Fe, Valencia, Spain
f Quantitative Imaging Biomarkers in Medicine (QUIBIM), Valencia, Spain
g i3S, Instituto de Investigacão e Inovação em Saúde, IBMC, Instituto de Biología Molecular y Celular, Oport, Portugal
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Aim

To compare pancreatic and hepatic steatosis quantified by proton density fat fraction (PDFF) on magnetic resonance imaging (MRI) in patients with chronic liver disease.

Material and Methods

This cross-sectional study included 46 adult patients who underwent liver biopsy for chronic viral hepatitis (n=19) or other chronic non-alcoholic liver diseases (NALD) (n=27). Liver biopsy was used as the gold standard for diagnosing and grading hepatic steatosis. All patients underwent clinical evaluation and MRI with a multi-echo chemical shift-encoded (MECSE) gradient-echo sequence for liver and pancreas PDFF quantification. We used Spearman’s correlation coefficient to determine the degree of association between hepatic PDFF and steatosis grade, and between pancreatic PDFF and steatosis grade and hepatic PDFF. To compare the chronic viral hepatitis group and the NALD group, we used t-tests for continuous or ordinal variables and chi-square tests for categorical variables.

Results

Hepatic PDFF measurements correlated with steatosis grades (RS=0.875, p<0.001). Pancreatic PDFF correlated with hepatic steatosis grades (RS=0.573, p<0.001) and hepatic PDFF measurements (RS=0.536, p<0.001). In the subgroup of patients with chronic NALD, the correlations remained significant between pancreatic PDFF and hepatic PDFF (RS=0.632, p<0.001) and between pancreatic PDFF and liver steatosis (RS=0.608, p<0.001); however, in the subgroup of patients with viral hepatitis these correlations were no longer significant.

Conclusion

Pancreatic fat deposition correlates with hepatic steatosis in patients with chronic NALD, but not in those with chronic viral hepatitis.

Keywords:
Adult
Pancreas
Liver
Steatosis
Chronic hepatitis
Liver disease
Magnetic resonance imaging
Resumen
Objetivo

Comparar la esteatosis pancreática y hepática mediante la determinación de la fracción de grasa por densidad protónica (FGDP) por resonancia magnética (RM) en pacientes con enfermedad hepática crónica.

Material y métodos

Estudio transversal de 46 pacientes adultos con biopsia hepática por hepatitis viral crónica (n=19) o por enfermedad hepática crónica no alcohólica (EHNA) (n=27). La biopsia de hígado se utilizó como referencia para la gradación de la esteatosis hepática. Todos los pacientes se sometieron a valoración clínica y estudio de RM con una secuencia eco de gradiente codificado por desplazamiento químico con múltiples ecos (MECSE) para la cuantificación de la FGDP en hígado y páncreas. Se utilizó el coeficiente de correlación de Spearman para calcular el grado de asociación entre la FGDP hepática y los grados de esteatosis por biopsia, y entre la FGDP pancreática y la afectación hepática (grados de esteatosis y FGDP).ElT-test se realizó para comparar variables continuas/ordinales en los grupos de hepatitis viral crónica y EHNA. Las variables categóricas se evaluaron mediante la prueba de χ2.

Resultados

Se observó una correlación significativa entre la FGDP hepática y los grados de esteatosis (RS=0,875, p< 0,001. También se evidenció una correlación positiva entre la FGDP del páncreas y la afectación hepática: grados de esteatosis RS = 0,573, p< 0,001 y FGDP RS = 0,536, p< 0,001. En el subgrupo de pacientes con EHNA crónica se mantuvo la correlación positiva significativa entre la FGDP pancreática y hepática RS = 0,632, p< 0,001 y con la esteatosis hepática RS = 0,608, p< 0,001. Estas relaciones se perdieron en el subgrupo de pacientes con hepatitis viral.

Conclusión

El depósito de grasa pancreática se correlaciona con la esteatosis hepática en pacientes con EHNA crónica. Esta relación se pierde en los pacientes con hepatitis viral crónica.

Palabras clave:
Adulto
Páncreas
Hígado
Esteatosis
Hepatitis crónica
Enfermedades del hígado
Resonancia magnética

Article

These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
M.M. Smits, E.J. van Geenen.
The clinical significance of pancreatic steatosis.
Nat Rev Gastroenterol Hepatol., 8 (2011), pp. 169-177
[2]
R.M. Feakins.
Obesity and metabolic syndrome: pathological effects on the gastrointestinal tract.
Histopathology., 68 (2016), pp. 630-640
[3]
A.R. Verma, V. Papalois.
Evaluating steatosis in pancreatic transplant.
Exp Clin Transplant., 9 (2011), pp. 159-164
[4]
K.E. Pinnick, S.C. Collins, C. Londos, D. Gauguier, A. Clark, B.A. Fielding.
Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition.
Obesity (Silver Spring), 16 (2008), pp. 522-530
[5]
V. Ratziu, F. Charlotte, A. Heurtier, S. Gombert, P. Giral, E. Bruckert, et al.
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Gastroenterology., 128 (2005), pp. 1898-1906
[6]
H. Tariq, S. Nayudu, S. Akella, M. Glandt, S. Chilimuri.
Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature.
Gastroenterology Res., 9 (2016), pp. 87-91
[7]
T. Khoury, A.W. Asombang, T.M. Berzin, J. Cohen, D.K. Pleskow, M. Mizrahi.
The Clinical Implications of Fatty Pancreas: A Concise Review.
Dig Dis Sci., 62 (2017), pp. 2658-2667
[8]
S.Y. Kim, H. Kim, J.Y. Cho, S. Lim, K. Cha, K.H. Lee, et al.
Quantitative Assessment of Pancreatic Fat by Using Unenhanced CT: Pathologic Correlation and Clinical Implications.
Radiology., 271 (2014), pp. 104-112
[9]
C.W. Hong, S. Fazeli Dehkordy, J.C. Hooker, G. Hamilton, C.B. Sirlin.
Fat Quantification in the Abdomen.
Top Magn Reson Imaging., 26 (2017), pp. 221-227
[10]
I.S. Idilman, A. Tuzun, B. Savas, A.H. Elhan, A. Celik, R. Idilman, et al.
Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease.
Abdom Imaging., 40 (2015), pp. 1512-1519
[11]
Z. Permutt, T.A. Le, M.R. Peterson, E. Seki, D.A. Brenner, C. Sirlin, et al.
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
Aliment Pharmacol Ther., 36 (2012), pp. 22-29
[12]
A. Tang, J. Tan, M. Sun, G. Hamilton, M. Bydder, T. Wolfson, et al.
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.
Radiology., 267 (2013), pp. 422-431
[13]
I.S. Idilman, H. Aniktar, R. Idilman, G. Kabacam, B. Savas, A. Elhan, et al.
Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.
Radiology., 267 (2013), pp. 767-775
[14]
M. Franca, A. Alberich-Bayarri, L. Marti-Bonmati, P. Oliveira, F.E. Costa, G. Porto, et al.
Accurate simultaneous quantification of liver steatosis and iron overload in diffuse liver diseases with MRI.
Abdom Radiol (NY)., 42 (2017), pp. 1434-1443
[15]
R. Olufadi, C.D. Byrne.
Clinical and laboratory diagnosis of the metabolic syndrome.
J Clin Pathol., 61 (2008), pp. 697-706
[16]
H. Yki-Jarvinen.
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
Lancet Diabetes Endocrinol., 2 (2014), pp. 901-910
[17]
C.T. Lim, R. Kumar.
Hepatitis B and concomitant hepatic steatosis.
Ann Transl Med., 5 (2017), pp. 38
[18]
E.J. Yoon, K.Q. Hu.
Hepatitis C virus (HCV) infection and hepatic steatosis.
Int J Med Sci., 3 (2006), pp. 53-56
[19]
S.B. Reeder, C.B. Sirlin.
Quantification of liver fat with magnetic resonance imaging.
Magn Reson Imaging Clin N Am., 18 (2010), pp. 337-357
[20]
W.C. Wu, C.Y. Wang.
Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study.
Cardiovasc Diabetol., 12 (2013), pp. 77
[21]
E.J. van Geenen, M.M. Smits, T.C. Schreuder, D.L. van der Peet, E. Bloemena, C.J. Mulder.
Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease.
Pancreas., 39 (2010), pp. 1185-1190
[22]
N.S. Patel, M.R. Peterson, D.A. Brenner, E. Heba, C. Sirlin, R. Loomba.
Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.
Aliment Pharmacol Ther., 37 (2013), pp. 630-639
[23]
E.M. Brunt, D.E. Kleiner, L.A. Wilson, P. Belt, B.A. Neuschwander-Tetri, Network NCR.
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.
Hepatology., 53 (2011), pp. 810-820
[24]
L. Marti-Bonmati, A. Alberich-Bayarri, J. Sanchez-Gonzalez.
Overload hepatitides: quanti-qualitative analysis.
Abdom Imaging., 37 (2012), pp. 180-187
[25]
J. Li, Y. Xie, F. Yuan, B. Song, C. Tang.
Noninvasive quantification of pancreatic fat in healthy male population using chemical shift magnetic resonance imaging: effect of aging on pancreatic fat content.
Pancreas., 40 (2011), pp. 295-299
[26]
J. Glaser, K. Stienecker.
Pancreas and aging: a study using ultrasonography.
Gerontology., 46 (2000), pp. 93-96
[27]
M. Sasaki, Y. Nakanuma, H. Ando.
Lipomatous pseudohypertrophy of the pancreas in a patient with cirrhosis due to chronic hepatitis B.
[28]
J. De Luca-Johnson, K.J. Wangensteen, J. Hanson, E. Krawitt, R. Wilcox.
Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.
Dig Dis Sci., 61 (2016), pp. 2710-2720
[29]
L.S. Szczepaniak, R.G. Victor, R. Mathur, M.D. Nelson, E.W. Szczepaniak, N. Tyer, et al.
Pancreatic steatosis and its relationship to beta-cell dysfunction in humans: racial and ethnic variations.
Diabetes Care., 35 (2012), pp. 2377-2383
[30]
M.K. Kim, H.J. Chun, J.H. Park, D.M. Yeo, K.-H. Baek, K.-H. Song, et al.
The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes.
Diabetes Research and Clinical Practice., 106 (2014), pp. 590-596
[31]
M. Hori, M. Takahashi, N. Hiraoka, T. Yamaji, M. Mutoh, R. Ishigamori, et al.
Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma.
Clin Transl Gastroenterol., 5 (2014), pp. e53
[32]
A. Mathur, H.A. Pitt, M. Marine, R. Saxena, C.M. Schmidt, T.J. Howard, et al.
Fatty pancreas: a factor in postoperative pancreatic fistula.
Ann Surg., 246 (2007), pp. 1058-1064
asdasdasd
Article options
Tools